Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01725113 · ClinicalTrials.gov registry record · Phase 4
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
A Phase 4 study, sponsored by Winthrop University Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT01725113 is a Phase 4 study that was terminated before completion, run by Winthrop University Hospital. The registered enrollment target is 16 participants.
The verdict
NCT01725113, a Phase 4 study, was terminated before completion, sponsored by Winthrop University Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.
Interventions
- DRUG Paricalcitol
- DRUG Calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01725113
The ClinicalTrials.gov registry entry for NCT01725113 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Winthrop University Hospital, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paricalcitol is the first listed.
NCT01725113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01725113 about?
NCT01725113 is a clinical study titled "Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol". The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.
What is the current status of trial NCT01725113?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2012-11. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01725113?
The interventions under investigation include: Paricalcitol (DRUG), Calcitriol (DRUG).
Who is sponsoring clinical trial NCT01725113?
This trial is sponsored by Winthrop University Hospital, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.